$118 Million is the total value of DAFNA Capital Management LLC's 72 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 150.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | Buy | LOXO ONCOLOGY INC | $12,654,000 | +182.0% | 300,722 | +115.2% | 10.70% | +171.5% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $4,545,000 | +989.9% | 541,128 | +721.1% | 3.84% | +950.3% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $3,299,000 | +62.2% | 82,500 | +13.8% | 2.79% | +56.1% |
| AGTC | Buy | APPLIED GENETIC TECHNOL CORP | $2,836,000 | +5.9% | 411,000 | +43.6% | 2.40% | +2.0% |
| ARDX | Buy | ARDELYX INC | $2,805,000 | +13.5% | 221,738 | +27.4% | 2.37% | +9.3% |
| MGNX | Buy | MACROGENICS INC | $2,217,000 | +21.6% | 119,200 | +33.6% | 1.88% | +17.0% |
| CLLS | New | CELLECTIS S Asponsored ads | $1,834,000 | – | 76,404 | +100.0% | 1.55% | – |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $1,626,000 | -2.2% | 208,458 | +30.4% | 1.38% | -5.9% |
| FOMX | Buy | FOAMIX PHARMACEUTICALS LTD | $1,612,000 | -45.8% | 325,667 | +21.5% | 1.36% | -47.9% |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $1,567,000 | – | 473,478 | +100.0% | 1.32% | – |
| SCYX | Buy | SCYNEXIS INC | $1,054,000 | +90.3% | 381,900 | +119.9% | 0.89% | +83.0% |
| BLRX | New | BIOLINERX LTDsponsored adr | $961,000 | – | 1,000,000 | +100.0% | 0.81% | – |
| VYGR | New | VOYAGER THERAPEUTICS INC | $944,000 | – | 71,320 | +100.0% | 0.80% | – |
| ARQL | Buy | ARQULE INC | $855,000 | +1.4% | 807,008 | +20.7% | 0.72% | -2.4% |
| NERV | New | MINERVA NEUROSCIENCES INC | $821,000 | – | 101,317 | +100.0% | 0.69% | – |
| CASC | New | CASCADIAN THERAPEUTICS INC | $767,000 | – | 185,259 | +100.0% | 0.65% | – |
| NEOS | Buy | NEOS THERAPEUTICS INC | $686,000 | +202.2% | 95,273 | +145.1% | 0.58% | +191.5% |
| AKBA | New | AKEBIA THERAPEUTICS INC | $648,000 | – | 70,455 | +100.0% | 0.55% | – |
| GEMP | New | GEMPHIRE THERAPEUTICS INC | $554,000 | – | 52,797 | +100.0% | 0.47% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $405,000 | – | 265,000 | +100.0% | 0.34% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC COM | $379,000 | – | 88,067 | +100.0% | 0.32% | – |
| OBSV | New | OBSEVA SA | $260,000 | – | 25,000 | +100.0% | 0.22% | – |
| BLCM | New | BELLICUM PHARMACEUTICALS INC | $247,000 | – | 20,000 | +100.0% | 0.21% | – |
| AXSM | New | AXSOME THERAPEUTICS INC | $217,000 | – | 55,700 | +100.0% | 0.18% | – |
| AFMD | New | AFFIMED THERAPEUTICS BV | $213,000 | – | 92,500 | +100.0% | 0.18% | – |
| ADMP | New | ADAMIS PHARMACEUTICALS CORP | $128,000 | – | 30,000 | +100.0% | 0.11% | – |
| ANAB | New | ANAPTYSBIO INC | $125,000 | – | 4,500 | +100.0% | 0.11% | – |
| TNXP | New | TONIX PHARMACEUTICALS HLDG C | $93,000 | – | 20,000 | +100.0% | 0.08% | – |
| BPMX | Buy | BIOPHARMX CORP | $58,000 | +100.0% | 115,000 | +49.3% | 0.05% | +96.0% |
| GALE | New | GALENA BIOPHARMA INC COM NEW | $28,000 | – | 46,145 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.